Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Nortriptyline for Relapsed Small Cell Carcinoma
NCT02881125Phase 1Completed
- Sponsor
- University of Washington
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nortriptyline in small cell carcinoma (SCC), sponsored by University of Washington. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Nov 2016; status: completed.
02
Drugs
nortriptyline
03
Conditions
small cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT02881125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881125.